ALUPENT
LOE ApproachingNDAINHALATIONSOLUTION
Approved
Jun 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is an inhaled bronchodilator solution approved in 1983 for respiratory indications requiring inhalation therapy. The product is a small-molecule formulation delivered via inhalation route as a solution dosage form. Specific mechanistic details and primary indications are not publicly detailed in available records.
LOE Approaching
With lifecycle stage at LOE approaching, commercial teams should expect declining headcount and focus on generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's late-stage lifecycle and minimal growth trajectory. Career opportunities on ALUPENT are primarily defensive roles focused on market maintenance and generic transition management rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.